FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893211377> ?p ?o ?g. }

• W2893211377 abstract "Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer. Besides their anti-tumour efficacy, several PKIs have also shown radiosensitizing effects when combined with external beam radiation. Based on these results we asked if the addition of PKIs offers a therapeutic opportunity to improve radioimmunotherapy (RIT) against ovarian cancer. Five PKIs (alisertib, MK1775, MK2206, saracatinib, temsirolimus) were chosen for cytotoxicity screenings based on their current clinical trials in the treatment of ovarian cancer and their influence on cell cycle regulation and DNA damage repair pathways. We combined selected PKIs with 177Lu-labelled anti-L1CAM monoclonal antibody chCE7 for our investigations.PKIs cytotoxicity was determined via cell colony-forming assays. Biomarker of DNA double-strand breaks (DSBs, γH2A.X) was analysed by western blot and fluorescence microscopy. Flow cytometric measurements were performed to evaluate levels of apoptosis based on mono- or combination treatments. The best combination was used for in vivo combination therapy studies in nude mice with SKOV3ip and IGROV1 human ovarian cancer xenografts. Bonferroni correction was used to determine statistical significance for multiple comparisons.The highest cytotoxicity against both cell lines was observed for MK1775 and alisertib. Combinations including 177Lu-labelled mAb chCE7 and MK1775 decreased 177Lu-DOTA-chCE7 IC60-values 14-fold, compared to 6-fold, when the radioimmunoconjugate was combined with alisertib. The most effective PKI MK1775 was further evaluated and demonstrated synergistic effects in combination with 177Lu-DOTA-chCE7 against IGROV1 cells. Significantly higher amounts of DSBs were detected in IGROV1 cells after combination (91%) compared to either treatment alone (MK1775: 52%; radioimmunoconjugate: 72%; p < 0.0125). Early-apoptosis was significantly enhanced in IGROV1 cells correlating with induced DSBs (177Lu-DOTA-chCE7: 8%, MK1775: 28%, 177Lu-DOTA-chCE7 + MK1775: 40%, p < 0.0125). Immunohistochemistry analysis of γH2A.X expression levels after therapy in SKOV3ip xenografts revealed a high sensitivity of the tumour cells to MK1775 and a high radioresistance. A prominent effect of tumour growth inhibition of the RIT and of the combination therapy was observed in vivo in a late stage IGROV1 xenograft model.Our results warrant further evaluation of combination of MK1775 and radioimmunotherapy." @default.
• W2893211377 created "2018-10-05" @default.
• W2893211377 creator A5010171315 @default.
• W2893211377 creator A5015362116 @default.
• W2893211377 creator A5035240508 @default.
• W2893211377 creator A5036321771 @default.
• W2893211377 creator A5041743198 @default.
• W2893211377 creator A5059525247 @default.
• W2893211377 creator A5061648511 @default.
• W2893211377 creator A5066158692 @default.
• W2893211377 creator A5077717166 @default.
• W2893211377 date "2018-09-25" @default.
• W2893211377 modified "2023-10-17" @default.
• W2893211377 title "Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma" @default.
• W2893211377 cites W127046385 @default.
• W2893211377 cites W1524628399 @default.
• W2893211377 cites W1543697093 @default.
• W2893211377 cites W1594627772 @default.
• W2893211377 cites W1600144936 @default.
• W2893211377 cites W1965037168 @default.
• W2893211377 cites W1965498557 @default.
• W2893211377 cites W1966932597 @default.
• W2893211377 cites W1976779081 @default.
• W2893211377 cites W1979760206 @default.
• W2893211377 cites W1985789005 @default.
• W2893211377 cites W1991403537 @default.
• W2893211377 cites W1996193504 @default.
• W2893211377 cites W2006621710 @default.
• W2893211377 cites W2020495169 @default.
• W2893211377 cites W2023529679 @default.
• W2893211377 cites W2024254984 @default.
• W2893211377 cites W2028495676 @default.
• W2893211377 cites W2031586165 @default.
• W2893211377 cites W2038126486 @default.
• W2893211377 cites W2038143768 @default.
• W2893211377 cites W2038619046 @default.
• W2893211377 cites W2057385701 @default.
• W2893211377 cites W2058426435 @default.
• W2893211377 cites W2061066809 @default.
• W2893211377 cites W2071788428 @default.
• W2893211377 cites W2071946439 @default.
• W2893211377 cites W2072974182 @default.
• W2893211377 cites W2079395808 @default.
• W2893211377 cites W2085739259 @default.
• W2893211377 cites W2086308175 @default.
• W2893211377 cites W2093442957 @default.
• W2893211377 cites W2097523044 @default.
• W2893211377 cites W2100078246 @default.
• W2893211377 cites W2105590267 @default.
• W2893211377 cites W2110691972 @default.
• W2893211377 cites W2123113463 @default.
• W2893211377 cites W2126614028 @default.
• W2893211377 cites W2127136362 @default.
• W2893211377 cites W2129040993 @default.
• W2893211377 cites W2132834292 @default.
• W2893211377 cites W2133506440 @default.
• W2893211377 cites W2134947875 @default.
• W2893211377 cites W2140894005 @default.
• W2893211377 cites W2147772438 @default.
• W2893211377 cites W2148636166 @default.
• W2893211377 cites W2159750196 @default.
• W2893211377 cites W2161394680 @default.
• W2893211377 cites W2163059465 @default.
• W2893211377 cites W2217850171 @default.
• W2893211377 cites W2328421677 @default.
• W2893211377 cites W2609150653 @default.
• W2893211377 cites W4248769580 @default.
• W2893211377 doi "https://doi.org/10.1186/s12885-018-4836-1" @default.
• W2893211377 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6156869" @default.
• W2893211377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30253737" @default.
• W2893211377 hasPublicationYear "2018" @default.
• W2893211377 type Work @default.
• W2893211377 sameAs 2893211377 @default.
• W2893211377 citedByCount "9" @default.
• W2893211377 countsByYear W28932113772019 @default.
• W2893211377 countsByYear W28932113772020 @default.
• W2893211377 countsByYear W28932113772021 @default.
• W2893211377 countsByYear W28932113772022 @default.
• W2893211377 countsByYear W28932113772023 @default.
• W2893211377 crossrefType "journal-article" @default.
• W2893211377 hasAuthorship W2893211377A5010171315 @default.
• W2893211377 hasAuthorship W2893211377A5015362116 @default.
• W2893211377 hasAuthorship W2893211377A5035240508 @default.
• W2893211377 hasAuthorship W2893211377A5036321771 @default.
• W2893211377 hasAuthorship W2893211377A5041743198 @default.
• W2893211377 hasAuthorship W2893211377A5059525247 @default.
• W2893211377 hasAuthorship W2893211377A5061648511 @default.
• W2893211377 hasAuthorship W2893211377A5066158692 @default.
• W2893211377 hasAuthorship W2893211377A5077717166 @default.
• W2893211377 hasBestOaLocation W28932113771 @default.
• W2893211377 hasConcept C109316439 @default.
• W2893211377 hasConcept C121608353 @default.
• W2893211377 hasConcept C126322002 @default.
• W2893211377 hasConcept C150903083 @default.
• W2893211377 hasConcept C159654299 @default.
• W2893211377 hasConcept C183713625 @default.
• W2893211377 hasConcept C190283241 @default.
• W2893211377 hasConcept C202751555 @default.
• W2893211377 hasConcept C203014093 @default.
• W2893211377 hasConcept C207001950 @default.

• next